Indium-111 bleomycin complex for radiochemotherapy of head and neck cancer – dosimetric and biokinetic aspects

Kalevi J.A. Kairemo^{1,3}, Hans A. Ramsay², Magnus Tagesson⁶, Antti P. Jekunen³, Timo K. Paavonen⁴, Hilkka A. Jääskelä-Saari², Kristian Liewendahl¹, Kaj Ljunggren⁶, Sauli Savolainen⁵, Sven-Erik Strand⁶

¹ Department of Clinical Chemistry, University Central Hospital of Helsinki, Finland

² Department of Otorhinolaryngology, University Central Hospital of Helsinki, Finland

³ Department of Oncology, University Central Hospital of Helsinki, Finland

⁴ Department of Pathology, University of Helsinki, Finland

⁵ Department of Physics, University of Helsinki, Finland

⁶ Department of Radiation Physics University of Lund, Sweden

Eur J Nucl Med (1996) 23: 631–638

By accident the appropriate reference to Fig. 6, which was added to the manuscript at the revision stage as an example of whole-body distribution of indium-111 bleomycin complex, was not included. The images presented in the figure are from a work in progress, presented in part in [1]. There is a typographical error in the legend: actually the activity source (3.7 MBq) is between the calves.

References

1. Huhmar H, Korppi-Tommola T, Aronen H, Kallio M, Färkkilä M, Penttilä P, Kairemo K, Savolainen S. In-111 labeled bleomycin uptake by brain tumours. Eur J Nucl Med (1995) 22: 869 (abstr).

Correspondence to: K.J.A. Kairemo